99 related articles for article (PubMed ID: 10095425)
61. Trametinib.
Zeiser R
Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
[TBL] [Abstract][Full Text] [Related]
62. Dabrafenib.
Kainthla R; Kim KB; Falchook GS
Recent Results Cancer Res; 2014; 201():227-40. PubMed ID: 24756796
[TBL] [Abstract][Full Text] [Related]
63. [Management of patients with melanoma].
Robert C; Cavalcanti A; Kolb F; Sarfati B; Moya-Plana A; Tomasic G; Mateus C
Rev Prat; 2014 Jan; 64(1):75-80. PubMed ID: 24649552
[TBL] [Abstract][Full Text] [Related]
64. Eruptive squamous cell carcinomas after vemurafenib therapy.
Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
[TBL] [Abstract][Full Text] [Related]
65. Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Ye Y; Li Q; Hu WL; Tseng HY; Jin L; Zhang XD; Zhang LJ; Yang S
Transl Oncol; 2013 Aug; 6(4):470-81. PubMed ID: 23908690
[TBL] [Abstract][Full Text] [Related]
66. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
67. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
68. [Analysis of BRAF mutation and extracellular regulated protein kinases activation in nasal mucosa melanomas].
Li HY; Zhou L; Tian J; Cong N
Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(48):3399-402. PubMed ID: 21223812
[TBL] [Abstract][Full Text] [Related]
69. Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA.
Zhu L; Kim K; Domenico DR; Appert HE; Howard JM
J Surg Oncol; 1996 Feb; 61(2):100-5. PubMed ID: 8606540
[TBL] [Abstract][Full Text] [Related]
70. Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations.
Scarpa A; Capelli P; Zamboni G; Oda T; Mukai K; Bonetti F; Martignoni G; Iacono C; Serio G; Hirohashi S
Am J Pathol; 1993 Apr; 142(4):1163-72. PubMed ID: 8475992
[TBL] [Abstract][Full Text] [Related]
71. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
[TBL] [Abstract][Full Text] [Related]
72. Osteosarcoma in blood relatives.
Longhi A; Benassi MS; Molendini L; Macchiagodena M; Picci P; Bacci G
Oncol Rep; 2001; 8(1):131-6. PubMed ID: 11115584
[TBL] [Abstract][Full Text] [Related]
73. [Genetic instability in osteoblastic tumors of the skeletal system].
Roessner A; Radig K; Schneider-Stock R; Mittler U; Neumann HW
Verh Dtsch Ges Pathol; 1998; 82():133-43. PubMed ID: 10095425
[TBL] [Abstract][Full Text] [Related]
74. Genetic instability in osteoblastic tumors of the skeletal system.
Radig K; Schneider-Stock R; Mittler U; Neumann HW; Roessner A
Pathol Res Pract; 1998; 194(10):669-77. PubMed ID: 9820862
[TBL] [Abstract][Full Text] [Related]
75. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
76. [Alterations of MDM2 and p53 genes in bone tumors].
Zhou X; Gao L; Zhe X
Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
